<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04892745</url>
  </required_header>
  <id_info>
    <org_study_id>APHP210098</org_study_id>
    <secondary_id>2020-A03337-32</secondary_id>
    <nct_id>NCT04892745</nct_id>
  </id_info>
  <brief_title>Impact of Hemodialysis on Cutaneo-muscular Electrical Impedance</brief_title>
  <acronym>H-ICMUS</acronym>
  <official_title>Impact of Hemodialysis on Cutaneo-muscular Electrical Impedance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this pilot study aims to describe the modifications of subcutaneous&#xD;
      impedancemetry induced by dialysis.&#xD;
&#xD;
      As secondary objectives, the study aims to 1) describe the modifications of cutaneo-muscular&#xD;
      impedancemetry induced by dialysis. 2) describe the relationship between modifications of&#xD;
      subcutaneous impedancemetry induced by dialysis and - technical conditions of dialysis; -&#xD;
      volemic parameters of dialysis; - evolution of liquid compartments in organism during&#xD;
      dialysis; - volemic events or neuromuscular events. 3) describe the relationship between&#xD;
      modifications of cutaneo-muscular impedancemetry induced by dialysis and 1) describe the&#xD;
      modifications of cutaneo-muscular impedance induced by dialysis. 2) describe the relationship&#xD;
      between modifications of subcutaneous impedancemetry induced by dialysis and - technical&#xD;
      conditions of dialysis; - volemic parameters of dialysis; - evolution of liquid compartments&#xD;
      in organism during dialysis; - volemic events or neuromuscular events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study will be realized in dialysis facility of Ambroise Paré hospital, APHP. The duration&#xD;
      of enrollment of subjects will be 3 months, each enrolled patient will has 2 or 3 week's&#xD;
      follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2021</start_date>
  <completion_date type="Anticipated">August 2021</completion_date>
  <primary_completion_date type="Anticipated">August 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Electrical parameters of subcutaneous impedancemetry</measure>
    <time_frame>at the end of study, up to 4 months</time_frame>
    <description>Electrical parameter extracellular resistance (Re) will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cutaneo-muscular impedancemetry assessement</measure>
    <time_frame>at the end of study, up to 4 months</time_frame>
    <description>Cutaneo-muscular impedancemetry will be assessed by extracellular resistance (Re).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Whole body impedancemetry assessement</measure>
    <time_frame>at the end of study, up to 4 months</time_frame>
    <description>Whole body impedancemetry will be assessed by Re.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of volemic or neuromuscular events</measure>
    <time_frame>at the end of study, up to 4 months</time_frame>
    <description>Incidence of volemic or neuromuscular events during the session, such as:&#xD;
peridialytic hypotension,&#xD;
crampses.</description>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Hemodialysis</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adult patients suffering chronic renal failure and undergoing chronic hemodialysis in&#xD;
        Ambroise Paré hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient ⩾ 18 years;&#xD;
&#xD;
          -  Patient undergoing chronic dialysis in hemodialysis facility of Ambroise Paré&#xD;
             hospital;&#xD;
&#xD;
          -  Patient has been informed and given no-opposition for participating to the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient with a pacemaker or an implantable cardioverter defibrillator;&#xD;
&#xD;
          -  Patient under guardianship or curatorship;&#xD;
&#xD;
          -  Foreign patient under french AME scheme.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie ESSIG, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Service de Néphrologie, Hôpital Ambroise Paré, APHP</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie ESSIG, MD, PhD</last_name>
    <phone>+ 33 1 49 09 56 48</phone>
    <email>marie.essig@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service de Néphrologie, Hôpital Ambroise Paré, APHP</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <zip>92100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 16, 2021</study_first_submitted>
  <study_first_submitted_qc>May 14, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 19, 2021</study_first_posted>
  <last_update_submitted>May 14, 2021</last_update_submitted>
  <last_update_submitted_qc>May 14, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hemodialysis</keyword>
  <keyword>electrical impedance</keyword>
  <keyword>subcutaneous impedancemetry</keyword>
  <keyword>cutaneo-muscular impedancemetry</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

